The Company's basic policy is to continue paying stable dividends while comprehensively considering factors such
as securing funds to prepare for long-term business development. Furthermore, the Company uses its retained
earnings for R&D investments, production equipment investments, and other measures to strengthen its corporate
structure for sustainable future growth. On the other hand, the Company recognizes that providing fair profit returns
in line with earnings is also an important management priority. Based on the "ASKA Pharmaceutical Holdings Takes
Action to Implement Management That is Conscious of Cost of Capital and Share Price" announced in November
2023, the Company adopts a performance-linked dividend policy, indicating shareholder returns with a dividend
payout ratio of approximately 30% as a guideline.
Based on the above policy and recent earnings trends, the Company plans to set the year-end dividend for the current
fiscal year at 33 yen per share, which, together with the interim dividend of 27 yen already paid, will result in an
annual dividend of 60 yen per share.
Regarding profit distribution for the next fiscal year, based on the "Notice Regarding Dividends of Surplus (Increase
in Dividend) and Changes to Dividend Policy" disclosed on May 11, 2026, the Company plans to set the total payout
ratio at 40% from the fiscal year ending March 31, 2027 onwards. Taking into account the introduction of a progressive
dividend policy (excluding special dividends), the Company plans to pay 65 yen per share (32 yen interim dividend
and 33 yen year-end dividend) as the annual dividend for the fiscal year ending March 2027
(As of May 11, 2026)